Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
RESEARCH TOOLSreports
Holding UNCY?
Track your performance easily
UNCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.20 - $1.82
Previous Close$0.46
Volume5.71M
Average Volume (3M)2.60M
Market Cap
$43.40M
Enterprise Value$44.04M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$634.00K
Price to Earnings (P/E)―
Beta-4.71
Next Earnings
Nov 12, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding94,356,212
10 Day Avg. Volume1,783,574
30 Day Avg. Volume2,601,909
Standard Deviation0.56
R-Squared0.04
Alpha-0.00317
Financial Highlights & Ratios
Price to Book (P/B)-2.88
Price to Sales (P/S)64.30
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit65.24
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$4.88Price Target Upside960.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Unicycive Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsUnicycive announced positive results from the safety and tolerability pivotal trial for phosphate binder, oxylanthanum carbonate.
Market OpportunityGiven the improvements to pill burden and potentially even efficacy based on the recent pivotal study, there is a multi-hundred million dollar opportunity for Unicycive that should flow through to shareholders in the form of a planned dividend for 75% of operating cash flow.
Regulatory ProgressUnicycive announced it has submitted the NDA for Oxylanthanum Carbonate (OLC) to treat hyperphospatemia in chronic kidney disease (CKD) patients on dialysis.
Bears Say
Regulatory ApprovalsRisks to the investment thesis, rating and target price include failure to secure regulatory approvals for OLC or UNI-494.
Regulatory UncertaintyThere is uncertainty surrounding both the TDAPA (transitional drug add-on payment adjustment) period and timing for CMS implementing the dialysis bundle.
Stock PerformanceUNCY shares have sold off over the past several quarters, likely due to the uncertainty surrounding the TDAPA period and timing for CMS implementing the dialysis bundle.
---
Ownership Overview
6.61%
Insiders
1.46% Mutual Funds
19.51% Other Institutional Investors
72.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.20 and its highest was $1.82 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Currently, no data Available
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Nov 12, 2024 which is 11 days ago.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on Aug 14, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.199 by $0.049.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -$0.15.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 94,356,210 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.199. Following the earnings report the stock price went up 33.333%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 1M.
---
Unicycive Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.88 (960.87% Upside)
$4.88 (960.87% Upside)
Hedge Fund Trend
Decreased
By 838.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.35%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
---
UNCY Stock 12 Month Forecast
Average Price Target
$4.88
▲(960.87% Upside)
Technical Analysis
Best Analysts Covering UNCY
1 Year
1 Year Success Rate
6/23 ratings generated profit
1 Year Average Return
-15.44%
reiterated a buy rating 3 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -15.44% per trade.
---